secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2026-05-13T20:03:13+00:00
Accession:  0000875320-26-000204
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal
--------------------------------------------------------------------------------

- All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
- Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).
- Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.
- 2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.
- Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/0000875320-26-000204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532026000204/vrtx-20260513.htm
  HTML page:      https://secwatch.observer/filing/0000875320-26-000204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer